13F Holdings
中文EN

VOR Vor Biopharma Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY155.3%
TTM EPS YoY177.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA402.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets127.6%
Debt / equity—
Current ratio13.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.09x
Accruals ratio438.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$321.53M$93.31M$94.31M$64.55M$47.53M
SG&A expense$50.11M$27.88M$31.72M$28.87M$21.49M
Operating income-$371.64M-$121.19M-$126.04M-$93.42M-$69.02M
Net income-$695.98M-$116.91M-$117.86M-$92.09M-$68.90M
EBITDA-$368.75M-$117.66M-$122.54M-$90.89M-$67.58M
EPS (basic)-70.50-34.03-1.75-2.33-2.10
EPS (diluted)-70.50-34.03-1.75-2.33-2.10
Weighted avg. shares (diluted)9.87M3.44M67.19M39.55M33.43M
Balance sheet
Cash & equivalents$396.49M$81.95M$31.36M$57.71M$119.80M
Short-term investments$58.72M$9.98M$105.81M$172.54M$87.67M
Current assets$458.11M$96.51M$140.80M$236.95M$214.40M
PP&E, net$533,000$6.58M$10.05M$12.63M$6.85M
Total assets$464.13M$142.89M$198.13M$299.37M$242.59M
Current liabilities$25.17M$18.61M$15.57M$13.12M$10.15M
Total liabilities$628.44M$46.23M$47.40M$48.76M$26.33M
Shareholders' equity-$164.31M$96.66M$150.72M$250.61M$216.26M
Shares outstanding38.72M6.24M67.89M66.00M37.17M
Cash flow statement
Operating cash flow-$142.71M-$99.66M-$100.29M-$85.14M-$69.14M
Capital expenditure$941,000$229,000$1.07M$8.46M$3.89M
Free cash flow-$143.65M-$99.89M-$101.36M-$93.61M-$73.04M
Investing cash flow-$48.80M$96.86M$71.01M-$94.09M-$91.65M
Financing cash flow$503.81M$53.39M$2.94M$117.14M$232.91M
Depreciation & amortization$2.89M$3.53M$3.49M$2.52M$1.43M
Stock-based compensation$18.91M$9.85M$13.36M$10.70M$4.32M
Dividends paid$0$0$0$0$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.